Antiviral, oncology company Genuine plots Hong Kong listing: Public Equity Report

Although at least two biotechs are still in a holding pattern as they seek to go public on NASDAQ, the next IPO by a biotech could be in Hong Kong, where Genuine has applied for a listing.

The antiviral and oncology company posted its prospectus on Tuesday, seeking to raise an undisclosed amount of cash on the Hong Kong exchange. In two private rounds across 2020-2022, Genuine Biotech Ltd. raised more than RMB700 million ($96.5 million), according to its filing...